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CCR2 upregulation in DRG neurons plays
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Abstract
Background: Diabetic gastropathy is a complex neuromuscular dysfunction of the stomach that commonly occurs in
diabetes mellitus. Diabetic patients often present with upper gastrointestinal symptoms, such as epigastric discomfort or
pain. The aim of this study was to assess gastric sensation in streptozocin-induced diabetes mellitus (DM) rats and to
determine the contribution of C-C motif chemokine receptor 2 (CCR2) signaling to gastric hyperalgesia.
Results: DM rats showed signs of neuropathy (cutaneous mechanical hyperalgesia) from two weeks after streptozocin
administration until the end of the experiment. Accelerated solid gastric emptying was observed at two weeks
after streptozocin administration compared to the controls. Intense gastric hyperalgesia also developed in DM rats
at two weeks after streptozocin administration, which was significantly reduced after intrathecal administration of
the CCR2 antagonist INCB3344. Immunochemical analysis indicated that CCR2 expression was substantially
upregulated in small and medium-sized dorsal root ganglia neurons of DM rats, although the protein level of monocyte
chemoattractant protein-1, the preferred ligand for CCR2, was not significantly different between the control and DM
groups.
Conclusions: These data suggest that CCR2 activation in nociceptive dorsal root ganglia neurons plays a role in the
pathogenesis of gastric hyperalgesia associated with diabetic gastropathy and that CCR2 antagonist may be a promising
treatment for therapeutic intervention.
Keywords
Neuropathic pain, diabetes mellitus, streptozocin, gastric hyperalgesia, CCR2 receptor
Date Received: 6 August 2017; revised: 8 September 2017; accepted: 21 November 2017
Background
Diabetes mellitus (DM) is a major global health problem
that affects 415 million people worldwide. Its prevalence
is predicted to increase to 642 million people (1 in
10 adults) by 2040.1 Diabetic neuropathy is one of the
most common complications of both type 1 and type 2
DM, and comprises sensory neuropathy, focal and mul-
tifocal neuropathies, and autonomic neuropathy.2
Approximately 50% of DM patients have some form
of neuropathy, with about one third suffering from
chronic pain symptoms.3 Diabetic sensory neuropathy
frequently coexists with autonomic dysfunction that
affects multiple organs in the body, including the gastro-
intestinal (GI) system.4
Diabetic gastropathy is the term for gastric neuro-
muscular dysfunctions in DM and is often associated
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with altered gastric emptying and GI symptoms. In mul-
tivariable analysis, significant weight loss and neuropa-
thy are respectively associated with the increased risk of
delayed and rapid gastric emptying.5 Upper GI symp-
toms in DM are also correlated to diabetic complica-
tions, particularly peripheral neuropathy.6,7 It is
noteworthy that gastropathy in DM not only exacer-
bates GI symptoms such as nausea, vomiting, bloating,
and upper abdominal pain but also impairs glycemic
control and has a negative impact on quality of life.8
As gastropathy is a serious health problem in DM, sev-
eral studies in recent decades have investigated its mech-
anisms and management. However, most reports focus
exclusively on gastric emptying. Gastric sensation
remains an important yet under-discussed issue in DM.
Furthermore, to our knowledge, the mechanisms of gas-
tric pain in DM have as yet not been investigated.
Chemokines and chemokine receptors, expressed by
immune and nerve cells, play a central role in the patho-
physiology of acute and chronic pain syndromes.9 They
induce neuromodulatory and neurotoxic effects directly
through the activation of G-protein-coupled receptors or
indirectly through neuron-glial interactions.10 Recent
studies have targeted monocyte chemoattractant protein
1 (MCP-1), the so-called C-C motif chemokine ligand 2,
and its preferred C-Cmotif chemokine receptor 2 (CCR2)
in the pathogenesis of neuropathic pain. Following
peripheral nerve injury, MCP-1 upregulation has been
demonstrated in sensory neurons of the dorsal root gan-
glion (DRG)11–13 and the spinal cord,14–16 as well as in
spinal microglia17 and astrocytes.13,15,18 Behavioral stud-
ies indicate that MCP-1 neutralizing antibody or CCR2
antagonists can reduce the mechanical allodynia induced
by nerve injury in rodent models.12,18–22 In addition,
mechanical allodynia after sciatic nerve ligation injury
is totally abolished in CCR2 knockout mice,17,23 indicat-
ing the essential role of MCP-1/CCR2 signaling in the
induction and maintenance of neuropathic pain.
Interestingly, Jamali et al.24 and Guan et al.25 further
report that serum MCP-1 level is significantly higher in
type 1 DM patients with multiple complications, includ-
ing diabetic neuropathy.
Prompted by the above reports, this study aimed to
assess gastric sensation by behavioral assay in the strep-
tozocin (STZ)-induced DM model. The effect of CCR2
antagonist on gastric hyperalgesia in vivo and the local-
ization of MCP-1 and CCR2 proteins in the DRG and
spinal cord were also investigated in this model.
Methods
Experimental animals
All experiments were performed on male Sprague-
Dawley rats (eight weeks, 250–300 g, obtained from
Sankyo Labo Service Corporation, Toyama, Japan).
The rats were housed in individual cages with ad libitum
access to food and water and maintained under a con-
trolled environment (23 1C, humidity 60 10%,
12/12 h light/dark cycle). The protocol was approved
by Kanazawa University’s Institutional Committee on
Animal Research, and all the experiments were per-
formed in accordance with the International
Association for the Study of Pain (IASP) guidelines for
the care and use of laboratory animals in research.
Induction of diabetes
Diabetes was induced in the experimental rats by a single
intraperitoneal (i.p.) injection of STZ (LKT
Laboratories, St. Paul, MN) at 45 mg/kg, prepared in
0.1 M citrate buffer (CB; pH 4.5), after overnight fast-
ing. Blood glucose level was determined biweekly from
the saphenous vein using a blood glucometer (Life
Check, Gunze, Kyoto, Japan). Animals with a level of
>250 mg/dl were regarded as hyperglycemic and were
placed in the experimental DM group. However, very
few (<10%) DM rats were removed from the study for
reasons of severe ill health. Exclusion criteria were exces-
sive weight loss (>20%), lack of activity with no respon-
siveness to behavioral tests, wound sepsis at the site of
the abdominal incision (which might interfere with elec-
tromyographic (EMG) recording data), and septicemia
via the intrathecal catheter. Age-matched control (CT)
rats received an equal volume of 0.1 M CB.
Evaluation of pain behavior
All behavioral experiments were performed biweekly for
10 weeks after STZ or CB administration.
Cutaneous mechanical hyperalgesia
Cutaneous mechanical hyperalgesia was assessed by the
Randall-Selitto paw pressure test, employing an analgesy
meter (Model 37215, Ugo Basile, Varese, Italy). The
probe tip of the machine was applied to the dorsal surface
of the rat’s left hind paw. The intensity of the pressure on
the probe was set to increase linearly from 0 to 250 g. The
nociceptive threshold was determined by the force (g) at
which the rat showed its withdrawal response. Successive
stimuli were applied to the left hind paw at 5-min intervals
five times, and the mean value after excluding the lowest
and highest intensities was assumed to be the paw with-
drawal threshold (PWT) of that animal.
Cutaneous mechanical allodynia
Cutaneous mechanical allodynia was examined using
von Frey’s method, employing a dynamic plantar esthe-
siometer (Model 37450, Ugo Basile). The rats were first
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acclimated to the testing environment by placement in a
clear plastic chamber with a metal mesh floor for about
30 min. Nociceptive threshold was measured by paw
withdrawal response to increasing vertical force of a
von Frey filament (preset force from 0 to 50 g in 10 s)
applied to the plantar surface of the right hind paw.
Measurements were repeated five times at approximately
5-min intervals. The PWT was defined as the mean value
of the record excluding the lowest and highest forces.
Cutaneous thermal hyperalgesia
The Hargreaves method was used to determine the ther-
mal hyperalgesia using a plantar test apparatus (Model
37370, Ugo Basile). The rats were habituated to the
apparatus by placement in a transparent Perspex enclo-
sure with a thin glass floor for about 30 min. A focused
beam of infrared heat was applied to the plantar surface
of the right hind paw. The intensity of the heat source
was maintained at 60 and the cut-off duration was 30 s.
Paw withdrawal latency was defined as the time at which
an abrupt withdrawal response of the hind paw was
observed. The procedure was repeated five times at
approximately 5-min intervals. The mean value, exclud-
ing the lowest and highest intensities, was taken for each
animal.
Gastric hyperalgesia
Gastric sensitivity was assessed by EMG recording from
the acromio-trapezius muscle response to gastric balloon
distention (GD), as previously described in Ozaki et al.26
Surgical procedure. One week before the recording
time, under anesthesia with sodium pentobarbital (i.p.,
50 mg/kg), a left lateral oblique epigastric incision was
made to permit insertion of a latex balloon ( 2.5 cm in
diameter) into the rat’s stomach through the fundus. The
polyethylene tube connected to the balloon for air infla-
tion was subcutaneously taken out from the nape of the
neck. Two wire electrodes (AS632, Cooner Wire, CA)
were implanted into the acromio-trapezius muscle for
EMG recording.
EMG recording. Each rat was first accommodated to the
EMG recording room for at least 30 min. The gastric
balloon was inflated to 60 mmHg pressure using the
sphygmomanometer. The visceromotor response
(VMR) of the acromio-trapezius muscle to GD was
recorded twice for 20 s at a 4-minute interval. Each
GD trial consisted of two parts: a 10-s pre-distension
period (baseline) and a 20-s gastric distension period.
Response to GD was defined as an increase in EMG
activity above the baseline during GD. The EMG data
were amplified, filtered (10,000, 300–5000 Hz; A-M
systems, Everett, WA), digitized, and integrated using
a SPIKE2/CED1401 data-acquisition interface. The
raw EMG was rectified and quantified by calculating
the area under the curve.
Assessment of gastric emptying
The rate of gastric emptying was determined by amber-
lite pellet assay as previously described in Matsuda et
al.27 The rat, which had fasted for 20 to 24 h but had
free access to water, was provided 100 amberlite pellets
(1 mm in diameter) into the stomach by oral tube. The
water supply was removed following insertion of the
pellets. After 2 h, the rat was euthanized with sodium
pentobarbital (i.p., 250 mg/kg). The stomach was then
surgically removed and the amberlite pellets remaining
inside the stomach were counted. The gastric emptying
rate for each rat was calculated according to the follow-
ing formula.
Gastric emptying rate %ð Þ ¼ A–Bð Þ=A 100
where A denotes the number of amberlite pellets inserted
into the stomach, and B denotes the number of amberlite
pellets remaining in the stomach after 2 h.
Intrathecal drug administration
At the time of gastric surgery for EMG recording, a
PE10 catheter (Becton, Dickinson and Company,
Franklin Lakes, NJ) was implanted into the intrathecal
space via a small cut opening on the atlanto-occipital
membrane. The tip of the catheter was placed at the
T10 level and fixed in the correct position using a few
sutures. After abdominal and/or intrathecal surgery, all
the rats received ciprofloxacin (i.p., 20 mg/kg in 0.1 N
HCl; Sigma-Aldrich, Tokyo, Japan) to prevent the type
of infections that usually develop with DM.
To evaluate the effect of the drug, DM rats with ultra-
sensitive response to GD (10-fold more sensitive than the
CT) were selectively placed in the therapeutic (pharma-
cology) group. Following EMG recording at two weeks
after STZ or CB administration, the animals received a
single intrathecal injection of CCR2 antagonist (25 ml of
INCB3344 in 10% DMSOþ saline; MedChem Express,
Princeton, NJ) or vehicle (10% DMSOþ saline). The
VMR to GD was then recorded again at 1, 2, 4, and
24 h after injection.
Immunohistochemistry
Both CT and DM groups were sacrificed at two weeks
after STZ or CB administration. The rats were deeply
anesthetized with sodium pentobarbital (i.p., 70 mg/kg)
and transcardially perfused with heparinized physiolog-
ical saline followed by 4% paraformaldehyde in 0.1 M
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phosphate buffer solution. The T10 DRG and spinal
cords were removed and post-fixed in the same fixative
overnight. The tissues were then cryoprotected in 30%
sucrose prepared in 0.1 M phosphate buffer saline at
4C, then rapidly frozen in optimal cutting temperature
compound (Sakura Finetek, Torrance, CA) and stored
at –80C. Spinal cord sections (15 mm) and DRG sec-
tions (10 mm) were cut using a cryostat, mounted on
glass slides and processed for immunofluorescence as
previously described.28
The sections were first allowed heat-mediated antigen
retrieval by 0.01 M CB (pH 6.0) and then blocked with
5% normal donkey serum in 0.1 M phosphate buffer
saline containing 0.3% Triton X-100 for 30 min at
room temperature. The sections were then incubated
overnight at 4C with primary antibodies for MCP-1
(rabbit, 1:500, Torrey Pines Biolabs, Secaucus, NJ),
CCR2 (rabbit, 1:200, Novus Biologicals LLC,
Littleton, CO), NeuN (mouse, 1:5000, Merck
Millipore, Billerica, MA), GFAP (mouse, 1:1000, Cell
Signaling Technology, Danvers, MA), and Iba-1 (goat,
1:500, Abcam, Cambridge, UK). The sections were then
incubated with donkey anti-rabbit IgG (HþL) Alexa
Fluor 594, donkey anti-goat IgG (HþL) Alexa Fluor
488, and goat anti-mouse IgG (HþL) Alexa Fluor 488
conjugated secondary antibodies (1:1000, Thermo Fisher
Scientific, Waltham, MA) for 1 h at room temperature.
Cell nuclei were stained with 40,6-diamidino-2-phenylin-
dole (Nacalai Tesque, Kyoto, Japan). The slides were
cover-slipped with Vectashield mounting media (Vector
Laboratories, Burlingame, CA) and examined under a
Zeiss LSM 5 Pascal Laser Scanning Confocal
Microscope (Carl Zeiss, Advanced Imaging
Microscopy, Jena, Germany). The stained sections
were analyzed using Image J software.
Western blot
The T10 DRG and spinal cords were taken from the rats
as soon as possible after sacrificing by cervical disloca-
tion at two weeks post-injection of STZ or CB. The
tissues were homogenized in a lysis buffer (20 mM
Tris-HCl pH 7.6, 150 mM NaCl, 1 mM ethylenedi-
aminetetraacetic acid, and 1 mM 1,4-dithiothreitol) con-
taining protease inhibitor cocktail (Nacalai Tesque).
Protein concentrations were determined using a Protein
Assay Rapid Kit (Wako Pure Chemicals Industries,
Osaka, Japan) with bovine serum albumin as the stan-
dard. DRG (5 mg) and spinal cord (10 mg) proteins were
separated by SDS-PAGE gel and transferred onto
PDVF membrane (Merck Millipore). The blotting mem-
branes were blocked with Blocking One (Nacalai
Tesque) for 30 min at room temperature, followed by
incubation with primary antibodies for MCP-1 (rabbit,
1:1000) and CCR2 (rabbit, 1:2000) overnight at 4C.
The blots were then incubated with HRP-conjugated
goat anti-rabbit IgG (HþL) secondary antibody
(1:10,000, Cell Signaling Technology) for 1 hour at
room temperature. The GAPDH antibody (mouse,
1:10,000, Acris Antibodies, San Diego, CA) was used
as the loading control. The protein bands were visualized
by chemiluminescent detection using ImmunoStar LD
(Wako Pure Chemicals Industries). The scanned
images (ImageQuant LAS 4000, GE Healthcare, Little
Chalfont, UK) were analyzed using image J software.28
Data analysis
Statistical analysis was performed using Sigma Plot 12.5
software (Systat Software Inc., San Jose, CA). Graphic
data were presented as mean SEM. All the behavioral
data were analyzed using one-way analysis of variance
(ANOVA), two-way ANOVA, or two-way repeated
measures ANOVA where appropriate, followed by the
Holm-Sidak method for multiple comparisons. Data
from immunohistochemistry (IHC) and Western blot
were analyzed using Student’s unpaired t-test. A value
of p< 0.05 was considered statistically significant.
Results
General changes in STZ-induced DM rats
Following administration of STZ, about 80% of the rats
developed DM, suffering from the usual symptoms of
diabetes such as polyuria, polydipsia, and polyphagia.
Despite a markedly increased food and water intake,
the DM rats showed no weight gain: their body weights
were constant throughout the experiment, unlike the
age-matched CT rats that showed weight gain
(Figure 1(a)). The blood glucose level was continuously
elevated (>250 mg/dl) in the DM group, starting from
three days after STZ administration until the end of the
experiment (10 weeks), whereas the CT group main-
tained their blood glucose level within the normoglyce-
mic range (Figure 1(b)).
Assessment of peripheral diabetic neuropathy. The develop-
ment of neuropathy in STZ-induced DM rats was con-
firmed by peripheral cutaneous mechanical and thermal
hypersensitivity tests. There was no significant difference
in cutaneous sensitivity between the experimental groups
before the induction of diabetes. STZ induced a sus-
tained and significant reduction of PWT as measured
by the Randall-Selitto Paw Pressure Test from two
weeks until the end of the experiment (p< 0.001 CT vs.
DM, two-way repeated measures ANOVA; p< 0.001,
one-way ANOVA for DM group, n¼ 6), whereas the
CT group showed no significant difference between
before and after treatment (Figure 2(a)). In von Frey’s
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filament test, the DM rats showed a lower mechanical
nociceptive threshold than the CT, starting from four
weeks after STZ administration, but this result was sta-
tistically significant only after eight weeks (p¼ 0.03 CT
vs. DM, n¼ 6) (Figure 2(b)). There was no significant
difference in response to thermal stimuli between the CT
and DM groups at any time point (p¼ 0.99, n¼ 6)
(Figure 2(c)). These results indicated that DM rats had
cutaneous mechanical hyperalgesia and allodynia, but
no change in thermal sensitivity.
Assessment of diabetic gastropathy. Altered gastric emptying
and upper abdominal pain are frequent symptoms of
diabetic gastropathy.5,29 In this study, the rate of 2-h
solid gastric emptying was significantly accelerated in
the DM group at two weeks after STZ as compared
with the CT group (p< 0.01, n¼ 6) (Figure 3(a)).
During that period, all DM rats discharged almost all
their stomach contents into the small intestine within 2
h postprandially, whereas the CT rats emptied about
half. The gastric emptying rate after four weeks in the
DM group was also faster than the CT, but the data
were not statistically significant (p¼ 0.14, n¼ 6). From
6 weeks, rapid gastric emptying was no longer observed
in DM rats.
In addition to gastric motor function, the sensitivity
of the stomach was also higher in DM rats than in the
CT rats according to the intragastric balloon
(a) (b)
Figure 1. Differences in body weight and blood glucose level between the control and diabetic groups. Body weight (a) and random blood
glucose level (b) were measured in the control (CT) and diabetic (DM) rats. Data are shown as mean SEM, *p< 0.001 CT versus DM,
n¼ 15–20 rats per group. No weight gain (a) and hyperglycemia (b) were observed in DM rats throughout the experiments.
(a) (b)
(c)
Figure 2. Changes in cutaneous sensitivities after induction of diabetes by STZ. The Randall-Selitto test (a), von Frey’s test (b), and heat
sensitivity test (c) were performed in control (CT) and diabetic (DM) rats. Data are shown as mean SEM, *p< 0.001, †p< 0.05 CT
versus DM, n¼ 6 rats per group. PWT measured by Randall-Selitto test (a) and von Frey’s test (b) was reduced in the STZ-induced DM
group.
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distension study. VMR to GD was substantially higher
in the DM group, especially at two weeks after STZ
administration (p< 0.001, n¼ 9) than in the CT group,
with significant levels at 2, 4, 8, and 10 weeks after STZ
administration (p< 0.01, n¼ 9) (Figure 3(b)). At two
weeks after STZ administration, approximately 40% of
DM rats showed ultrasensitive behavior to GD, i.e.,
about 10-fold the sensitivity seen in the CT rats (Figure
3(c)). This ultrasensitive response in DM rats was not
otherwise observed at any other time point. These find-
ings suggest that rapid gastric emptying and severe gastric
hyperalgesia develop in the early phase of DM.
CCR2 and gastric hypersensitivity in DM
Chemokine MCP-1 and its preferred receptor CCR2 are
well known to be involved in the development and main-
tenance of neuropathic pain.9,23 In this study, DM rats
that had shown an ultrasensitive response to GD at two
weeks after STZ administration were selectively used to
continue the therapeutic option for gaining clear evi-
dence on the effects of the drug. Intrathecal application
of CCR2 antagonist INCB3344 both time and dose
dependently suppressed established gastric hyperalgesia
in the STZ-induced DM model (Figure 4). Gastric
hyperalgesia in DM rats was significantly attenuated
by INCB3344 (1 mM and 0.1 mM) at 1 h (p< 0.01,
n¼ 5–7) and 2 h (p< 0.05) after administration as com-
pared with vehicle-treated rats. Gastric hyperalgesia was
also slightly lessened in DM rats at 4 h (p¼ 0.44 for
(a) (b)
(c)
Figure 3. Effect of STZ-induced diabetes on gastric motor and sensory functions. Gastric emptying (a) and gastric sensitivity (b) were
assessed in control (CT) and diabetic (DM) rats. Data are shown as mean SEM, *p< 0.001, #p< 0.01 CT versus DM. (a) Significantly
rapid gastric emptying was observed in DM rats at two weeks after STZ administration (n¼ 6 rats per group). (b) Distension-induced
gastric hyperalgesia developed significantly in DM rats (n¼ 9 rats per group). (c) Representative EMG recording data from each CT and
DM rats.
Figure 4. Effect of CCR2 antagonist (INCB3344) on diabetes-
induced gastric hyperalgesia. Gastric sensitivity was measured in
the control (CT) and diabetic (DM) rats at two weeks after STZ
administration. The CCR2 antagonist INCB3344 (CCR2-A) or
vehicle (veh) was injected intrathecally. Data are shown as mean
 SEM, #p< 0.01, †p< 0.05 veh versus CCR2-A, n¼ 5–7 rats per
group. INCB3344 (1 mM and 0.1 mM) significantly suppressed
distension-induced gastric hyperalgesia in DM rats at 1 and 2
h after administration as compared with vehicle-treated rats.
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1 mM and p¼ 0.34 for 0.1 mM) and 24 h (p¼ 0.41 for
1 mM and p¼ 0.11 for 0.1 mM) after injection, but these
data were not significant. A very low dose (0.01 mM) of
INCB3344 had no significant effect on gastric hyperal-
gesia at any time point after injection (p¼ 0.95 vehicle
vs. INCB3344, n¼ 5–6). There was no change in gastric
sensitivity in CT rats before and after treatment. This
finding suggests CCR2 signaling to be involved in the
development of diabetes-induced gastric hyperalgesia
but is not the sole determinant of gastric sensitivity
under normal physiological conditions.
CCR2 expression in DRG and spinal cord
To determine the mechanism of CCR2 involvement in
diabetes-induced gastric hyperalgesia, immunolocalization
of CCR2 and its protein level were investigated in T10
DRG and the spinal cord at two weeks after STZ admin-
istration. In the DRG sections, CCR2-immunoreactivity
(IR) was exclusively observed in neurons rather than in
non-neuronal cells in both CT and DM rats (Figure 5(a)
and (b)). The mean number of CCR2-expressed neurons
per section was significantly greater in the DM group
(20% of total, p< 0.001, n¼ 4) than in the CT (4% of
total) (Figure 5(e)), although there was no significant
difference in the mean number of total DRG neurons
per section between them (p¼ 0.87, n¼ 4) (Figure 5(c)).
DRG neurons were classified by cell diameter into small
( 30 mm), medium (31–44 mm), and large ( 45 mm)
categories according to Zhang et al.13 There was no sig-
nificant difference in the size distribution of DRG neu-




Figure 5. Cellular localization of CCR2-IR in T10 DRG at two weeks after STZ administration. Representative images of immunostaining
with anti-CCR2 antibody in control (CT) (a) and diabetic (DM) (b) rats. Arrows represent CCR2-positive cells. Scale bar: 50 mm. Number
of total and CCR2-IR neurons per section (c, e) and their size distribution (d, f) were determined in both the CTand DM groups. Data are
shown as mean SEM, *p< 0.001 CT versus DM, n¼ 4 rats per group. CCR2 was exclusively expressed in small- and medium-sized DRG
neurons in both the CTand DM rats (a, b, f). CCR2-IR neurons were significantly more numerous in the DM group than in the CT (a, b, e)
despite no significant change between them in total DRG neurons per section (c). The number of CCR2-IR cells was relatively greater in
small DRG neurons of DM rats according to the size distribution of the DRG neurons (d, f).
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and p¼ 0.57 for small-, medium-, and large-sized neu-
rons, respectively, n¼ 4) (Figure 5(d)). In both groups, a
considerable number of CCR2-IR neurons (70%–80%)
were small and the remaining (20%–30%) were medium
sized, but the numbers were much higher in the DM rats
than in the CT (Figure 5(f)). No CCR2-IR was found in
the large DRG neurons.
In spinal cord sections, the expression of CCR2 pro-
tein was restricted exclusively to the superficial layer of
the spinal dorsal horn, especially in the lamina I area;
only a few were seen in lamina II (Figure 6(a) and (b)).
No CCR2 immunolabeling was detected in any other
dorsal horn regions, including motor neurons, or in
non-neuronal glial cells, as revealed by double-labeling
IHC with glial cell markers (data not shown). Western
blot analysis indicated that the CCR2 protein level was
slightly higher in the DM group than in the CT group,
but this was not statistically significant (p¼ 0.45, n¼ 3)
(Figure 6(c) and (d)). These data show CCR2 signaling
to be substantially activated in the DRG neurons of
STZ-induced DM rats.
Expression of MCP-1 in DRG and the spinal cord
MCP-1 is the preferred ligand for CCR2, and these
interactions play an essential role in the pathophysiology
of neuroinflammatory diseases.9,10 To determine the
possible involvement of MCP-1 in diabetes-induced gas-
tric hyperalgesia, MCP-1 protein expression in T10
DRG and the spinal cord were also identified in both
the CT and DM groups. IHC staining indicated MCP-1
immunolabeling to be extensively localized in the DRG
neurons of both CT and DM rats, but its upregulation
would not be expected in the DM group compared to the
CT (Figure 7(a) and (b)). Western blot analysis also
supported the IHC finding that the mean expression
levels of MCP-1 were closely similar in both CT and
DM groups (p¼ 1.00, n¼ 3) (Figure 7(c) and (d)).
In spinal cord tissues, MCP-1 was widely expressed in
the astrocytes of the whole spinal cord area (Figure 8(a)
to (e)) and a few were also seen in the motor neurons of
the ventral horn regions (data not shown). Western blot




Figure 6. CCR2 protein expression in T10 spinal cord at two weeks after STZ administration. Representative images of immunostaining
with anti-CCR2 antibody in control (CT) (a) and diabetic (DM) (b) rats. Arrows represent CCR2-positive regions. (a2) and (b2) are higher
magnification images of white-boxed regions in (a1) and (b1), respectively. Scale bar: 50 mm. CCR2-IR was detected only in the superficial
layer of the spinal dorsal horn (n¼ 4 rats per group). (c) Representative Western blot analyses using anti-CCR2 and GAPDH antibodies.
GAPDH was used as a loading control. CT 1–3: CT rats; DM 1–3: DM rats. (d) Semi-quantitative densitometric data for CCR2-IR are
shown. Data are shown as mean SEM, n¼ 3 rats per group. The CCR2 protein level in the spinal cord was not significantly different
between the CT and DM groups.
8 Molecular Pain
higher in DM than in the CT group, but the data were
not statistically significant (p¼ 0.25, n¼ 3) (Figure 8(f)
and (g)). These findings indicate that chemokine MCP-1
is expressed in the neurons of the DRG and in the non-
neuronal cells of the spinal cord, but its upregulation
was not observed in the DM group.
Discussion
Diabetic neuropathy is a chronic deteriorating compli-
cation characteristic of both type 1 and type 2 DM,
affecting multiple organs and systems throughout the
whole body. Diabetic gastropathy is a term that embra-
ces a number of neuromuscular disorders of the stom-
ach, including the gastric emptying dysfunction. The
regulation of gastric emptying is undoubtedly multifac-
torial, consisting of the normal functions of gastric
motility, GI hormones, and neuronal reflex.30
Although gastroparesis is a well-known late complica-
tion of DM, rapid gastric emptying has also been
reported in some clinical and preclinical studies in the
early phase of both type 1 and type 2 DM. Solid gastric
emptying was accelerated in obese type 2 DM patients
without overt autonomic neuropathy when compared
with obese non-diabetic patients.31 Schwartz et al.32
also found a rapid gastric emptying of solid pancake
meal in type 2 DM patients compared with the controls
with similar BMI. Accelerated solid gastric emptying
was also observed in the first one to two weeks in
NOD/LtJ mice and in STZ-induced DM rats.33,34 In
agreement with the previous findings, this study also
exhibited unambiguously accelerated solid gastric emp-
tying in DM rats at two weeks after STZ administration.
Diabetic patients often present with GI symptoms
that include nausea, vomiting, bloating, and epigastric
pain that result from alterations in gastric emptying. In
spite of a great deal of research having been conducted
on gastric emptying, studies of gastric sensations are
rare: only two investigations have reported an increased
sensory response to gastric distension in type 1 DM
patients compared with healthy controls.35,36 Similar
findings were observed in this study: that DM rats had
higher sensitivity to GD than did age-matched CT rats
(Figure 3(b)), and furthermore, that hypersensitive
VMR to GD in DM rats was partially but significantly
reversed for at least 2 h by intrathecal injection of the
CCR2 antagonist INCB3344 (1 mM and 0.1 mM)
(Figure 4). It was consistent with other neuropathic
pain studies in which mechanical and thermal hyperal-
gesia after peripheral nerve injury were inhibited by
CCR2 antagonists.18,21,22
Upregulation of CCR2 is convincingly recorded in all
studies of neuropathic pain, although its cellular locali-
zation remains highly controversial, as it varies accord-
ing to the species and antibodies used, presenting within
DRG neurons,11,13,18,20,37 dorsal horn neurons,15,38
astrocytes,39 and microglia23,40 of the spinal cord. In
the present study, CCR2 expression was substantially
increased in the DRG neurons of DM rats, whereas it
was hardly detectable in CT sections (Figure 5(e)).
CCR2-IR cells were notably restricted to small- and
medium-sized DRG neurons (Figure 5(f)), as well as in
(a) (b)
(c) (d)
Figure 7. Immunolocalization of MCP-1 and its protein level in T10 DRG at two weeks after STZ administration. Representative images
of immunostaining with anti-MCP-1 antibody in control (CT) (a) and diabetic (DM) (b) rats. Scale bar: 50 mm. MCP-1 was constitutively
expressed in DRG neurons in both CTand DM rats (n¼ 4 rats per group). (c) Representative Western blot analyses using anti-MCP-1 and
GAPDH antibodies are shown. GAPDH was used as a loading control. CT 1–3: CT rats; DM 1–3: DM rats. (d) Semi-quantitative
densitometric data for MCP-1-IR is shown. Data are shown as mean SEM, n¼ 3 rats per group. There was no difference in MCP-1
protein levels between the CT and DM groups.
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the most superficial laminae of the spinal dorsal horn
(Figure 6(a) and (b)). It is well known that almost all
nociceptive C and Ad fibers possess small cell bodies,
and their central terminals project to the superficial
dorsal horn (lamina I and II) of the spinal cord.41
Both behavioral and IHC findings therefore suggest
that increased CCR2 signaling in neurons of the DRG
and spinal cord plays a major role in the pathogenesis of
distension-induced gastric hyperalgesia in DM.
CCR2 is the preferred receptor, with a higher affinity
for MCP-1.42 Several studies have revealed the
contribution of MCP-1/CCR2 signaling to the processes
of inflammatory and neuropathic pain in animal models.
Activation of MCP-1 induces the initiation and mainte-
nance of pain via a dual mechanism that involves the
central sensitization of neurons and neuron-glial inter-
actions.9 In primary neuronal culture, pre-incubation of
MCP-1 augmented capsaicin-evoked cationic currents in
small-diameter DRG neurons.43 Application of MCP-1
increased excitatory synaptic transmission and enhanced
NMDA- and AMPA-induced currents in lamina II neu-
rons of the spinal dorsal horn.15 MCP-1 also potentially
(a1) (a2) (b1) (b2)
(c1) (c2) (c3) (c4)
(d1) (d2) (d3) (d4)
(e1) (e2) (e3) (e4)
(f) (g)
Figure 8. Immunolocalization of MCP-1 and its protein level in T10 spinal cord at two weeks after STZ administration. Representative
images of immunostaining with anti-MCP-1 antibody in control (CT) (a) and diabetic (DM) (b) rats. (a2) and (b2) are higher magnification
images of white-boxed regions in (a1) and (b1), respectively. Scale bar: 50 mm. MCP-1 was expressed in the whole spinal cord (n¼ 4 rats
per group). Double-labeling IHC showed MCP-1 to be co-localized with astrocyte marker (GFAP) (c), but not with microglial (Iba1) (d) and
neuronal (NeuN) (e) markers. Scale bar: 50 mm. (f) Representative Western blot analyses using anti-MCP-1 and GAPDH antibodies are
shown. GAPDH was used as a loading control. CT 1–3: CTrats; DM 1–3: DM rats. (g) Semi-quantitative densitometric data for MCP-1-IR
are shown. Data are shown as mean SEM, n¼ 3 rats per group. The MCP-1 protein level was higher in the DM group than in the CT
group, but the data were not significant.
10 Molecular Pain
inhibited GABA-induced currents via GABAA receptors
in a primary culture of spinal cord neurons.38
Recent studies have revealed that MCP-1/CCR2 sig-
naling is also mediated by neuron-glial interactions in
nociceptive transmission. Ji et al.44 postulate that MCP-
1/CCR2-mediated neuron-microglial interaction is
involved in the induction of neuropathic pain, whereas
MCP-1/CCR2 mediated astrocyte-neuron signaling
takes part in the maintenance of neuropathic pain. It
has been supported by the following studies: The time
course of MCP-1 upregulation in DRG neurons was par-
allel to that of microglial activation after nerve
injury.12,16 Intrathecal injection of MCP-1 neutralizing
antibody or CCR2 antagonists inhibited microglial acti-
vation in neuropathic pain models.12,17,21 MCP-1-
induced microglial activation and nerve injury-induced
phosphorylation of p38 mitogen-activated protein
kinase (MAPK) in spinal microglia was diminished in
CCR2 knockout mice.17,23 MCP-1 expression was pri-
marily upregulated in astrocytes of the spinal cord and
trigeminal nucleus, but not in sensory neurons in some
neuropathic pain studies.15,19,22 Transgenic mice overex-
pressing MCP-1 in astrocytes were hypersensitive to
pain.45 In addition, Zhang and De Koninck16 noted
that early microglial activation induced by MCP-1-
expressed damaged neurons contributed to the initiation
of neuropathic pain, whereas delayed astrocyte activation
was crucial in maintaining long-lasting hypersensitivity.
Based on previous studies of diabetic neuropathy,
activation of spinal microglia in the dorsal horn has
been demonstrated in the STZ-induced DM model,
which was started from the early phase of DM (1–2
weeks) and lasted for six months.46,47,48 Changes in
mechanical allodynia in these animals were positively
correlated with microglial activation (both morphology
and function). Interestingly, spinal astrocytes did not
appear to play a part in diabetic neuropathic pain, as
they manifested no change47 or even decreased in
number.46,48 In this study, neither microglia nor astro-
cyte changes were significantly apparent in DM rats at
two weeks after STZ administration, compared with CT
rats (data not shown). It was probably explained by the
low concentration and different route of administration
of STZ used in this study. Another disagreement with
the conclusions of other neuropathic pain studies is that
significant upregulation of MCP-1 expression was not
likely to occur in neurons and glial cells of DM rats,
although its receptor CCR2 expression was extensively
increased in DRG neurons at two weeks after STZ
administration. However, microglial activation in the
previous findings of diabetic neuropathy became more
exacerbated and prominent over time,46,47 which does
not rule out microglial activation and MCP-1 upregula-
tion in the later phase of DM in this study. Nevertheless,
our findings demonstrate that CCR2 activation in
nociceptive DRG neurons is somewhat related to early
diabetic neuropathy. It can be further concluded from
the collected data that MCP-1/CCR2 signaling-mediated
gastric hyperalgesia in the early phase of DM is likely to
be chiefly the consequence of central sensitization of sen-
sory neurons rather than neuron-glial interactions. DM
induces over-sensitization of CCR2 in small- and
medium-sized DRG neurons, promoting the transduc-
tion and transmission of nociceptive signals to the cen-
tral nervous system and is involved in the facilitation
and modulation of pain via the other chemical mediators
produced by the cells along the nociceptive pathways.
In the past decade, a number of preclinical studies
have been conducted to clarify the underlying mecha-
nisms of MCP-1/CCR2 signaling in neuropathic pain.
As a classical G protein-coupled receptor, CCR2 activa-
tion induces the phosphorylation of multiple signal
transduction pathways including phospholipase C, pro-
tein kinase C, phosphatidylinositol-3 kinase, extracellu-
lar signal-regulated kinase (ERK) 1/2, and p38
MAPK.49 Following peripheral nerve injury, CCR2 acti-
vation increased the sensitizations of transient receptor
potential vanilloid 1 (TRPV1), transient receptor poten-
tial cation channel, subfamily A, member 1, and
tetrodotoxin-resistant Nav1.8 sodium channels in
DRG neurons that were mediated by protein kinase C
and phospholipase C activation.11,50 Activated CCR2
receptors on presynaptic terminals lead to increased glu-
tamate release in synaptic junctions that were dependent
on TRPV1 receptor activation.51 Moreover, MCP-1/
CCR2 signaling potentiated the TRPV1 and Nav1.8
receptor functions, enhanced the excitability of DRG
neurons, and promoted nociceptive transmission via
the activation of the phosphatidylinositol-3 kinase/Akt
(protein kinase B) signaling pathway, but not the ERK
activation pathway.43 In contrast, MCP-1 or nerve
injury-evoked mechanical allodynia was directly corre-
lated to increased phosphorylation of ERK 1/2 and
upregulation of proinflammatory mediators (interleu-
kin-1b, interleukin-6, cyclooxygenase-2, and nitric
oxide synthase 2), which were prevented by administra-
tion of CCR2 antagonist, ERK inhibitor, or TRPV1
receptor antagonist.21,51 In this study, we suggest that
CCR2 activation in small- and medium-sized DRG neu-
rons induces the sensitization of TRPV1 or Nav1.8
channels through the activation of MAPK signaling
pathways; however, further investigations are needed.
Conclusion
We have demonstrated for the first time that CCR2 acti-
vation in DRG neurons plays an integral role in gastric
hyperalgesia related to diabetic gastropathy. The evi-
dence of alleviation of diabetes-induced gastric hyper-
algesia by CCR2 antagonist in vivo suggests the
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potential use of CCR2 antagonist for therapeutic inter-
vention in diabetes gastropathy.
Authors’ note
Shinichiro Hiraga is now associated with Department of
Functional Anatomy, Graduate School of Medical Science,
Kanazawa University, Ishikawa, Japan.
Authors’ contributions
AAM, NO, and HO designed the project and NO, HO, and
KH supervised the experiments. AAM, YK, TN, and SH per-
formed the animal models, surgeries, and conducted the behav-
ioral experiments. AAM, TN, and YS carried out the general
assessment of diabetes, gastric emptying, and immunochemical
studies. AAM, NO, HO, and KH analyzed the data and wrote
the manuscript.
Acknowledgments
The authors are grateful to Ms. Rumi Shima and the partic-
ipants in this research for their invaluable advice and excellent
technical support.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This study was supported by Grants-in-Aid for
Scientific Research from Ministry of Education, Culture,
Sports, Science and Technology (Grant number 25460718,
2013).
References
1. International Diabetes Federation. IDF Diabetes Atlas,
7th ed. 2015, https://www.idf.org/e-library/epidemiology-
research/diabetes-atlas.html
2. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neurop-
athies: a statement by the American Diabetes Association.
Diabetes Care 2005; 28: 956–962.
3. Feldman EL. Epidemiology and classification of diabetic
neuropathy – up to date, https://www.uptodate.com (2015,
accessed 5 January 2017).
4. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic auto-
nomic neuropathy. Diabetes Care 2003; 26: 1553–1579.
5. Bharucha AE, Camilleri M, Forstrom L, et al.
Relationship between clinical features and gastric empty-
ing disturbances in diabetes mellitus. Clin Endocrinol 2009;
70: 415–420.
6. Bytzer P, Talley NJ, Hammer J, et al. GI symptoms in
diabetes mellitus are associated with both poor glycemic
control and diabetic complications. Am J Gastroenterol
2002; 97: 604–611.
7. Enck P, Rathmann W, Spiekermann M, et al. Prevalence
of gastrointestinal symptoms in diabetic patients and non-
diabetic subjects. Z Gastroenterol 1994; 32: 637–641.
8. Kong MF and Horowitz M. Gastric emptying in diabetes
mellitus: relationship to blood-glucose control. Clin Geriatr
Med 1999; 15: 321–338.
9. White FA, Jung H and Miller RJ. Chemokines and the
pathophysiology of neuropathic pain. Proc Natl Acad Sci
USA 2007; 104: 20151–20158.
10. Jung H, Toth PT, White FA, et al. Monocyte chemoat-
tractant protein-1 functions as a neuromodulator in dorsal
root ganglia neurons. J Neurochem 2008; 104: 254–263.
11. Ramesh G, MacLean AG and Philipp MT. Cytokines and
chemokines at the crossroads of neuroinflammation, neu-
rodegeneration, and neuropathic pain. Mediators Inflamm
2013; 2013: 480739.
12. Thacker MA, Clark AK, Bishop T, et al. CCL2 is a key
mediator of microglia activation in neuropathic pain
states. Eur J Pain 2009; 13: 263–272.
13. Zhang H, Boyette-Davis JA, Kosturakis AK, et al.
Induction of monocyte chemoattractant protein-1
(MCP-1) and its receptor CCR2 in primary sensory neu-
rons contributes to paclitaxel-induced peripheral neuropa-
thy. J Pain 2013; 14: 1031–1044.
14. Dansereau MA, Gosselin RD, Pohl M, et al. Spinal CCL2
pronociceptive action is no longer effective in CCR2 recep-
tor antagonist-treated rats. J Neurochem 2008; 106:
757–769.
15. Gao YJ, Zhang L, Samad OA, et al. JNK-induced MCP-1
production in spinal cord astrocytes contributes to central
sensitization and neuropathic pain. J Neurosci 2009; 29:
4096–4108.
16. Zhang J and De Koninck Y. Spatial and temporal rela-
tionship between monocyte chemoattractant protein-1
expression and spinal glial activation following peripheral
nerve injury. J Neurochem 2006; 97: 772–783.
17. Zhang J, Shi XQ, Echeverry S, et al. Expression of CCR2
in both resident and bone marrow-derived microglia plays
a critical role in neuropathic pain. J Neurosci 2007; 27:
12396–12406.
18. Zhu X, Cao S, Zhu MD, et al. Contribution of chemokine
CCL2/CCR2 signaling in the dorsal root ganglion and
spinal cord to the maintenance of neuropathic pain in a
rat model of lumbar disc herniation. J Pain 2014; 15:
516–526.
19. Dauvergne C, Molet J, Re´aux-Le Goazigo A, et al.
Implication of the chemokine CCL2 in trigeminal nocicep-
tion and traumatic neuropathic orofacial pain. EJP 2014;
18: 360–375.
20. Jeon SM, Sung JK and Cho HJ. Expression of monocyte
chemoattractant protein-1 and its induction by tumor
necrosis factor receptor 1 in sensory neurons in the ventral
rhizotomy model of neuropathic pain. Neuroscience 2011;
190: 354–366.
21. Van-Steenwinckel J, Re´aux-Le Goazigo A, Pommier B, et
al. CCL2 released from neuronal synaptic vesicles in the
spinal cord is a major mediator of local inflammation and
12 Molecular Pain
pain after peripheral nerve injury. J Neurosci 2011; 31:
5865–5875.
22. Zhang ZJ, Dong YL, Lu Y, et al. Chemokine CCL2 and its
receptor CCR2 in the medullary dorsal horn are involved in
trigeminal neuropathic pain. J Neuroinflamm 2012; 9: 136.
23. Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neu-
ropathic pain responses in mice lacking the chemokine
receptor CCR2. PNAS 2003; 100: 7947–7952.
24. Jamali Z, Nazari M, Khoramdelazad H, et al. Expression
of CC chemokines CCL2, CCL5, and CCL11 is associated
with duration of disease and complications in Type-1 dia-
betes: a study on Iranian diabetic patients. Clin Lab 2013;
59: 993–1001.
25. Guan R, Purohit S, Wang H, et al. Chemokine (C-C motif)
ligand 2 (CCL2) in sera of patients with type 1 diabetes and
diabetic complications. PLoS One 2011; 6: e17822.
26. Ozaki N, Bielefeldt K, Sengupta JN, et al. Models of gas-
tric hyperalgesia in the rat. Am J Physiol Gastrointest Liver
Physiol 2002; 283: G666–G676.
27. Matsuda M, Aono M, Moriga M, et al. Centrally admin-
istered neuropeptide Y (NPY) inhibits gastric emptying
and intestinal transit in the rat. Digest Dis Sci 1993; 38:
845–850.
28. Okuda H, Tatsumi K, Morita-Takemura S, et al.
Hedgehog signaling modulates the release of gliotransmit-
ters from cultured cerebellar astrocytes. Neurochem Res
2016; 41: 278–289.
29. Bytzer P, Talley NJ, Jones MP, et al. Oral hypoglycaemic
drugs and gastrointestinal symptoms in diabetes mellitus.
Aliment Pharmacol Ther 2001; 15: 137–142.
30. Burks TF, Galligan JJ, Porreca F, et al. Regulation of
gastric emptying. Fed Proc 1985; 44: 2897–2901.
31. Bertin E, Schneider N, Abdelli N, et al. Gastric emptying is
accelerated in obese type 2 diabetic patients without auto-
nomic neuropathy. Diabetes Metab 2001; 27: 357–364.
32. Schwartz JG, Green GM, Guan D, et al. Rapid gastric
emptying of a solid pancake meal in type II diabetic
patients. Diabetes Care 1996; 19: 468–471.
33. Ariga H, Imai K, Chen C, et al. Does ghrelin explain accel-
erated gastric emptying in the early stages of diabetes mel-
litus? Am J Physiol Regul Integr Comp Physiol 2008; 294:
R1807–R1812.
34. Choi KM, Zhu J, Stoltz GJ, et al. Determination of gastric
emptying in nonobese diabetic mice. Am J Physiol
Gastrointest Liver Physiol 2007; 293: G1039–G1045.
35. Rayner CK, Verhagen MA, Hebbard GS, et al. Proximal
gastric compliance and perception of distension in type 1
diabetes mellitus: effects of hyperglycemia. Am J
Gastroenterol 2000; 95: 1175–1183.
36. SamsomM, Salet GA, Roelofs JM, et al. Compliance of the
proximal stomach and dyspeptic symptoms in patients with
type I diabetes mellitus. Dig Dis Sci 1995; 40: 2037–2042.
37. Belkouch M, Dansereau MA, Re´aux-Le Goazigo A, et al.
The chemokine CCL2 increases Nav1.8 sodium channel
activity in primary sensory neurons through a Gbc-depen-
dent mechanism. J Neurosci 2011; 31: 18381–18390.
38. Gosselin RD, Varela C, Banisadr G, et al. Constitutive
expression of CCR2 chemokine receptor and inhibition
by MCP-1/CCL2 of GABA-induced currents in spinal
cord neurones. J Neurochem 2005; 95: 1023–1034.
39. Knerlich-Lukoschus F, Juraschek M, Blomer U, et al.
Force-dependent development of neuropathic central
pain and time-related CCL2/CCR2 expression after
graded spinal cord contusion injuries of the rat. J
Neurotrauma 2008; 25: 427–448.
40. Hu JH, Wu MY, Tao M, et al. Changes in protein expres-
sion and distribution of spinal CCR2 in a rat model of
bone cancer pain. Brain Res 2013; 1509: 1–7.
41. Bourne S, Machado AG and Nagel SJ. Basic anatomy and
physiology of pain pathways. Neurosurg Clin N Am 2014;
25: 629–638.
42. White FA, Bhangoo SK and Miller RJ. Chemokines: inte-
grators of pain and inflammation. Nat Rev Drug Discov
2005; 4: 834–844.
43. Kao DJ, Li AH, Chen JC, et al. CC-chemokine ligand 2
upregulates the current density and expression of TRPV1
channels and Nav1.8 sodium channels in dorsal root gan-
glion neurons. J Neuroinflammation 2012; 9: 189.
44. Ji RR, Xu ZZ and Gao YJ. Emerging targets in
neuroinflammation-driven chronic pain. Nat Rev Drug
Discov 2014; 13: 533–548.
45. Menetski J, Mistry S, Lu M, et al. Mice overexpressing
chemokine ligand 2 (CCL2) in astrocytes display enhanced
nociceptive responses. Neuroscience 2007; 149: 706–714.
46. Cheng KI, Wang HC, Chuang YT, et al. Persistent
mechanical allodynia positively correlates with an increase
in activated microglia and increased P-p38 mitogen-
activated protein kinase activation in streptozotocin-
induced diabetic rats. EJP 2014; 18: 162–173.
47. Tsuda M, Ueno H, Kataoka A, et al. Activation of dorsal
horn microglia contributes to diabetes-induced tactile allo-
dynia via extracellular signal-regulated protein kinase sig-
naling. Glia 2008; 56: 378–386.
48. Wodarski R, Clark AK, Grist J, et al. Gabapentin reverses
microglial activation in the spinal cord of streptozotocin-
induced diabetic rats. Eur J Pain 2009; 13: 807–811.
49. Bajetto A, Bonavia R, Barbero S, et al. Characterization of
chemokines and their receptors in the central nervous
system: physiopathological implications. J Neurochem
2002; 82: 1311–1329.
50. Zhao R, Pei GX, Cong R, et al. PKC-NF-kB are involved
in CCL2-induced Nav1.8 expression and channel function
in dorsal root ganglion neurons. Biosci Rep 2014; 34:
e00111.
51. Spicarova D, Adamek P, Kalynovska N, et al. TRPV1
receptor inhibition decreases CCL2-induced hyperalgesia.
Neuropharmacology 2014; 81: 75–84.
Aye-Mon et al. 13
